We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Dhx1.8

Dihexa Research

Mostly mechanism / observationalLimited safety

5 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Dihexa studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from mixed-quality studies published 2013–2026.

Based on 5 studies

Confidence

Low confidence

By outcome

Neurodegeneration (preclinical)Promotes new synapse formation in cell and animal studies; an angiotensin-IV analog developed (preclinically) toward Alzheimer's/Parkinson's. Unproven and unstudied in humans. · Not established (no human data)
Mostly mechanism / observational3 studies
Cognition & memory (preclinical)Improves learning and memory in rodent dementia models, with an HGF/c-Met mechanism proposed in preclinical work that includes a retracted paper. No published human data despite heavy marketing, and a theoretical proliferative concern that is not a proven risk. · Not established (no human data)
Too few graded studies2 studies
Safety profile
Too few graded studies1 study

Active research area

2 studies in the last 5 years

201320192026

1Review2026

Rahman OF et al. · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)

Recovery-enhancing agents such as epithalon, delta sleep-inducing peptide, and pinealon target circadian and mitochondrial regulators, and neuroactive peptides like selank, semax, and dihexa enhance brain-derived neurotrophic factor and HGF/c-Met pathways critical to neuroplasticity.
Although preclinical studies are promising, there is a current lack of clinical trials.
This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.

View source

2ReviewCited 35×2015

In plain English: Small-molecule angiotensin IV analogs are being developed to treat Alzheimer's and Parkinson's diseases.

Wright, Kawas, Harding · Progress in neurobiology (2015)

Review of angiotensin-IV analog development including dihexa
Summarizes procognitive preclinical evidence and drug-development rationale
Notes the absence of clinical data

View source

3ReviewCited 27×2015

In plain English: The brain HGF/c-Met receptor system is a target for treating Alzheimer's disease.

Wright, Harding · Journal of Alzheimer's disease : JAD (2015)

Review of the HGF/c-Met system as a neurotherapeutic target
Provides the mechanistic backdrop for dihexa's proposed action
Discusses growth-factor signaling in the brain

View source

4AnimalExpression of concernCited 44×2013

In plain English: Metabolically stabilized angiotensin IV analogs act as procognitive/antidementia agents in preclinical models.

McCoy, Benoist, Wright, Kawas, Bule-Ghogare, Zhu · The Journal of pharmacology and experimental therapeutics (2013)

Preclinical development paper for stabilized angiotensin-IV analogs including dihexa
Demonstrated procognitive activity and improved metabolic stability/BBB penetration
Rodent and biochemical characterization

View source Free full text

5AnimalCited 1×2024

In plain English: An angiotensin IV analog improved outcomes in a chemically induced Huntington's-disease-like rodent model.

Wells, Azzam, Hiller, Sardinia · Journal of Huntington's disease (2024)

Recent animal study of an angiotensin-IV analog in a Huntington's model
Reports neuroprotective/behavioral benefit in rodents
Extends the preclinical evidence to another disease model

View source Free full text

View in Research Library

Dihexa Research

Mostly mechanism / observational

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.

The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease.

Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.

Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats.